PhysioMedics is a healthcare technology company which provides online software solutions to reduce costs and improve efficiencies in managing musculoskeletal disorders.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
Elasmogen Ltd, a biopharmaceutical company, discovers and develops sight-saving therapies for inflammatory eye diseases. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER (humanized clinical candidate) available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, etc. Elasmogen Ltd has strategic partnerships with Almac Discovery Ltd and Merck Inc. The company was founded in 2014 and is based in Aberdeen, United Kingdom.
Axol Bioscience Ltd. is a biotechnology company based in Little Chesterford, United Kingdom, specializing in human cell culture systems for medical research, disease modeling, and drug discovery. The company produces a variety of human cells, including iPSC-derived cells like cardiomyocytes and neural stem cells, as well as primary cells such as endothelial and muscle cells. Axol also offers essential media and reagents, including cell culture media and growth supplements, to support researchers in their work. Additionally, the company provides custom services such as cell and tissue sourcing, iPSC reprogramming, differentiation into various cell types, and genome editing. Axol's products and services are utilized by pharmaceutical companies and research institutions worldwide, with distribution channels spanning multiple countries. Established in 2012, Axol is located in a notable innovation hub, Chesterford Research Park, in Cambridge, UK.
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
Talking Medicines Limited is a data technology company based in Glasgow and London that specializes in capturing, curating, and structuring patient insights related to launched medicines. Utilizing advanced artificial intelligence, machine learning, and natural language processing, the company analyzes real-world conversations and behaviors of patients to map their experiences with medications. Its flagship application, Medsmart, collects data on medication usage, providing pharmaceutical companies with real-time intelligence about patient sentiment and behavior. The company offers various solutions, including a real-world persona data service, digital focus groups, and custom data solutions tailored to specific needs within the pharmaceutical sector. Founded in 2013 and rebranded in 2015, Talking Medicines aims to enhance regulatory compliance and enable marketing strategies through insights that measure patient confidence and identify growth opportunities for pharmaceutical brands.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. Founded in 2017, the company focuses on creating microbiome-modulating drugs derived from bacterial communities in the human gastrointestinal tract. These products aim to restore health and prevent bacterial infections by addressing imbalances in gut bacteria associated with various diseases. EnteroBiotix is dedicated to developing both allogenic and autologous microbial therapeutics to meet the needs of patients with serious unmet medical conditions, thereby enabling healthcare providers to effectively prevent and treat debilitating infections and diseases.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Bio-Images Drug Delivery Ltd, located in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers comprehensive services that include troubleshooting, formulation development, and both in vitro and in vivo testing. A key feature of their offerings is the patented OralogiK technology, which allows for precise control of drug release. This technology has been validated in clinical studies and enables the oral administration of single, multi-dose, or combination drugs at specific intervals ranging from one to twelve hours after ingestion. The benefits of this system include targeted night-time dosing, multi-phased drug delivery, and the ability to direct drugs to specific areas within the digestive system. Additionally, Bio-Images Drug Delivery employs gamma scintigraphy to assess the in vivo behavior of formulations, providing crucial data on disintegration times, gastric emptying, and gastrointestinal transit. The company's clinical division supports the entire clinical trial process, from protocol development to regulatory submissions and the production of compliant study reports.
Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, founded in 2017. The company specializes in targeted protein degradation technology, which is aimed at developing innovative cancer therapeutics. Amphista's approach leverages the body's natural processes to selectively degrade and eliminate proteins that contribute to disease progression. By advancing next-generation therapeutics, the company seeks to improve treatment efficacy and enhance patient outcomes across a range of diseases. Amphista's research focuses on identifying novel methods to modulate the cell's degradation machinery, thereby addressing the underlying mechanisms of various conditions.
MiAlgae Ltd, founded in 2016 and based in Edinburgh, United Kingdom, specializes in the production of microalgal products designed to replace fishmeal in livestock feeds. The company focuses on creating nutrient-rich supplements high in Omega-3 fatty acids and proteins, essential for aquaculture and other livestock. By utilizing wastewater remediation in its production process, MiAlgae operates within a circular economy framework, which helps lower production costs and enhances competitiveness in the £340 billion global livestock feed industry. This innovative approach not only contributes to sustainable livestock production but also addresses the growing demand for alternative protein sources in animal nutrition.
ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. Founded in 2017, the company focuses on creating microbiome-modulating drugs derived from bacterial communities in the human gastrointestinal tract. These products aim to restore health and prevent bacterial infections by addressing imbalances in gut bacteria associated with various diseases. EnteroBiotix is dedicated to developing both allogenic and autologous microbial therapeutics to meet the needs of patients with serious unmet medical conditions, thereby enabling healthcare providers to effectively prevent and treat debilitating infections and diseases.
Talking Medicines Limited is a data technology company based in Glasgow and London that specializes in capturing, curating, and structuring patient insights related to launched medicines. Utilizing advanced artificial intelligence, machine learning, and natural language processing, the company analyzes real-world conversations and behaviors of patients to map their experiences with medications. Its flagship application, Medsmart, collects data on medication usage, providing pharmaceutical companies with real-time intelligence about patient sentiment and behavior. The company offers various solutions, including a real-world persona data service, digital focus groups, and custom data solutions tailored to specific needs within the pharmaceutical sector. Founded in 2013 and rebranded in 2015, Talking Medicines aims to enhance regulatory compliance and enable marketing strategies through insights that measure patient confidence and identify growth opportunities for pharmaceutical brands.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
Bio-Images Drug Delivery Ltd, located in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers comprehensive services that include troubleshooting, formulation development, and both in vitro and in vivo testing. A key feature of their offerings is the patented OralogiK technology, which allows for precise control of drug release. This technology has been validated in clinical studies and enables the oral administration of single, multi-dose, or combination drugs at specific intervals ranging from one to twelve hours after ingestion. The benefits of this system include targeted night-time dosing, multi-phased drug delivery, and the ability to direct drugs to specific areas within the digestive system. Additionally, Bio-Images Drug Delivery employs gamma scintigraphy to assess the in vivo behavior of formulations, providing crucial data on disintegration times, gastric emptying, and gastrointestinal transit. The company's clinical division supports the entire clinical trial process, from protocol development to regulatory submissions and the production of compliant study reports.
TC BioPharm’s mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life.
TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.
DuPont Teijin Films is a leading global producer of PET and PEN polyester films, specialising in film products and related services for the Healthcare, Photovoltaics, Durable Labels, Imaging Media, Flexible Electronics, Packaging, Electrical Insulation, Capacitors Industries and many more. We have dedicated marketing, technical and manufacturing operations worldwide
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
Causeway Therapeutics Ltd is a biopharmaceutical company based in Glasgow, United Kingdom, that specializes in developing microRNA products aimed at treating tendon injuries and disorders in both humans and horses. Founded in 2015 as a spin-out from the University of Glasgow, the company has leveraged academic research to create innovative therapies in the orthobiologic space. Its primary products include EquiMiR, designed to treat equine tendinopathy by mimicking natural microRNA with enhanced pharmacological properties, and TenoMiR, which restores critical microRNA levels to improve tendon health and strength. The company's focus on microRNA therapy is supported by a solid foundation of intellectual property and scientific evidence demonstrating its efficacy in addressing tendinopathies.
Ryboquin™ uses its expertise to turn under-developed intellectual property ideas into viable commercial realities. Founded in Scotland, Ryboquin Ltd is a privately held, virtual pharmaceutical company focused on commercialising patented technologies in the area of human cancer medicine.
Founded in Scotland, Ryboquin is a privately held, virtual pharmaceutical company focused on commercializing patented technologies in the area of human cancer medicine.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. Founded in 2017, the company focuses on creating microbiome-modulating drugs derived from bacterial communities in the human gastrointestinal tract. These products aim to restore health and prevent bacterial infections by addressing imbalances in gut bacteria associated with various diseases. EnteroBiotix is dedicated to developing both allogenic and autologous microbial therapeutics to meet the needs of patients with serious unmet medical conditions, thereby enabling healthcare providers to effectively prevent and treat debilitating infections and diseases.
Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.
Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
Elasmogen Ltd, a biopharmaceutical company, discovers and develops sight-saving therapies for inflammatory eye diseases. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER (humanized clinical candidate) available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, etc. Elasmogen Ltd has strategic partnerships with Almac Discovery Ltd and Merck Inc. The company was founded in 2014 and is based in Aberdeen, United Kingdom.
Elasmogen Ltd, a biopharmaceutical company, discovers and develops sight-saving therapies for inflammatory eye diseases. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER (humanized clinical candidate) available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, etc. Elasmogen Ltd has strategic partnerships with Almac Discovery Ltd and Merck Inc. The company was founded in 2014 and is based in Aberdeen, United Kingdom.
TC BioPharm’s mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life.
TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.
Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy.
MOFgen Ltd is an award winning VC-backed SME spin-out from the University of St Andrews and is the first company to commercialise MOFs for medical and therapeutic applications. The company’s patented technology was pioneered in the laboratories of world renowned porous material scientist Prof Russell Morris FRS within the School of Chemistry at St Andrews. With roots in the leading research group of its field, MOFgen is exploiting its strong IP and knowhow assets in the areas of MOF design, application, manufacturing and formulation to deliver cutting edge solutions to healthcare challenges. Through an ethos of innovation and collaboration, MOFgen works closely with its partners, to develop bespoke solutions to prevent healthcare associated infections, avoid bacterial resistance, heal chronic wounds and address arterial access.
Mironid Limited is a drug discovery company focused on developing therapeutic candidates aimed at treating degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014 and based in Newhouse, United Kingdom, Mironid employs a unique Physiology Mirroring Approach to design assays that replicate the drug target's conformation and environment found in living cells. The company's pipeline features Novel ShoLo compounds for chronic inflammatory diseases and Novel LoAc compounds for degenerative kidney diseases. By modulating the activity of key cell signaling proteins, Mironid aims to create high-value therapeutics that address significant unmet medical needs, thereby enhancing the health and quality of life for patients.
Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.
Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.
Calcivis Limited is a dental biologic and device manufacturing company based in Edinburgh, United Kingdom, focused on addressing tooth decay and enhancing preventive dentistry. Established in 2012, the company has developed a unique imaging system that provides live visualization of active tooth demineralization. This system incorporates CALCIVIS photoprotein, which emits light in response to free calcium ions released from demineralizing tooth surfaces. The imaging device captures this reaction, allowing dental professionals to assess and diagnose caries and other demineralization conditions effectively. By enabling early detection of active decay, the technology supports a preventive approach to dentistry, aiming to treat patients before cavities necessitate more invasive procedures. Calcivis was co-invented with contributions from the University of Dundee and LUX Innovate, and it operates a virtual development model in collaboration with various Scottish contract research and manufacturing organizations.
Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, specializing in the design and supply of tuneable peptide hydrogels for various applications in cell culture research. Established in 2012, the company focuses on providing hydrogels that closely mimic the chemical and physical properties of natural tissues, enabling researchers to grow, proliferate, and manipulate cells within realistic 3D environments. Their products are utilized in fundamental cell research, toxicology and drug development, as well as cancer cell research, and aim to replace animal testing methods. Biogelx's patented hydrogel systems are marketed globally, offering academic institutions, medical researchers, and pharmaceutical companies a competitive alternative to existing 3D cell culture solutions. Additionally, these hydrogels hold potential for future applications in cell therapy and regenerative medicine.
Clyde Biosciences Ltd. specializes in developmental drug testing solutions, focusing on cardiac cell analysis to provide insights into drug mechanisms and toxicity. The company has developed cellOPTIQ, an optical action potential assay that helps clients assess the cardiotoxicity risk of new and existing drugs by evaluating their effects on human cells. Additionally, Clyde Biosciences offers XTENDSR, which allows for direct measurements of drug-induced changes in cardiac sarcoplasmic reticulum function. By delivering human-relevant cardiomyocyte functional data, the company aids pharmaceutical and biotechnology firms in mitigating risks during drug development. Founded in 2012 and based in Glasgow, United Kingdom, Clyde Biosciences serves clients both domestically and internationally.
ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2014. The company specializes in optical molecular imaging technology that facilitates image-guided therapy for the detection, diagnosis, and monitoring of diseases. It focuses on the discovery and development of small molecules and peptides that can be conjugated with fluorescent dyes, allowing for real-time disease detection during interventional procedures, such as surgery. Edinburgh Molecular Imaging has raised over £15 million in non-dilutive funding from organizations like the Wellcome Trust, EPSRC, and MRC to advance its innovative SMART Agents, which enhance molecular imaging capabilities. The team behind the company comprises experienced scientists and clinicians with extensive expertise in medicinal chemistry, biochemistry, cell biology, and clinical development, positioning the company to contribute significantly to the field of medical imaging.
Elasmogen Ltd, a biopharmaceutical company, discovers and develops sight-saving therapies for inflammatory eye diseases. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER (humanized clinical candidate) available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, etc. Elasmogen Ltd has strategic partnerships with Almac Discovery Ltd and Merck Inc. The company was founded in 2014 and is based in Aberdeen, United Kingdom.
ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.
Fixed Phage was founded with the aim of developing new products for various industries from our platform technology. Each of our core technologies is comprehensively described and protected by our IP portfolio. We work at our custom designed laboratory and support infrastructure facilities located at the prestigious West of Scotland Science Park. Our in-house abilities include all work required to identify, manufacture and work with bacteriophage. Fixed Phage continually invests in innovation and our team presents at conferences and exhibitions around the world. To learn about whether we will be presenting near you, please follow us on social media.
Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.
Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, specializing in the design and supply of tuneable peptide hydrogels for various applications in cell culture research. Established in 2012, the company focuses on providing hydrogels that closely mimic the chemical and physical properties of natural tissues, enabling researchers to grow, proliferate, and manipulate cells within realistic 3D environments. Their products are utilized in fundamental cell research, toxicology and drug development, as well as cancer cell research, and aim to replace animal testing methods. Biogelx's patented hydrogel systems are marketed globally, offering academic institutions, medical researchers, and pharmaceutical companies a competitive alternative to existing 3D cell culture solutions. Additionally, these hydrogels hold potential for future applications in cell therapy and regenerative medicine.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
TPP is a UK-based preclinical-stage drug development company focused on nervous system disorders, immunology, and oncology. They in-license and develop intellectual properties obtained from research institutions, and the resultant products are either distributed via spin-outs or through licensing to the biotech/pharmaceutical sector.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.
CXR Biosciences is advancing and commercializing innovative approaches to transform the drug development and chemical safety assessment process. As well as introducing new technology platforms to the marketplace, CXR also helps customers to take their candidate compounds through development efficiently, or to resolve problems that have been encountered, through the provision of customized solutions. The company has business relationships with over sixty customers and collaborators, including pharmaceutical companies, chemical companies, biotechnology companies, leading universities and research institutions.
Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.
DC Biosciences Ltd specializes in providing proteomics services and molecular biology solutions to pharmaceutical and biotech companies, facilitating the development of drugs. The company offers a comprehensive technology portfolio, focusing on quantitative proteomics to support preclinical activities in drug discovery. Its services include biomarker discovery and validation, as well as drug re-profiling and repositioning. Key products offered by DC Biosciences include stable isotope labeling with amino acids in cell culture (SILAC) reagents, such as SILAC cell culture media and dialysed sera for SILAC applications, along with click chemistry reagents. Established in 2006 and originally known as Dundee Cell Products Ltd, the company rebranded to DC Biosciences Ltd in 2016 and is headquartered in Dundee, United Kingdom.
Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.
Nandi Proteins Limited is a technology-driven company based in Edinburgh, United Kingdom, focused on enhancing the functional properties of proteins in food manufacturing and nutrition. Established in 2000 and spun out of Heriot Watt University in 2001, the company specializes in patented processes that improve common proteins such as whey, egg, and soy. Nandi Proteins aims to be a leader in denatured protein technology, facilitating growth through direct trading of value-added proteins and strategic licensing agreements with industry partners. Its innovative approach employs a combination of heat, time, and temperature control to modify proteins, enabling food and beverage manufacturers to achieve desirable characteristics and health benefits while efficiently extracting valuable components like enzymes.
Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.